Comparative Pharmacology
Head-to-head clinical analysis: DECABID versus TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECABID versus TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE.
DECABID vs TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Decabid is a combination of chlorpheniramine (antihistamine) and pseudoephedrine (decongestant). Chlorpheniramine competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine acts as a sympathomimetic agent, stimulating alpha-adrenergic receptors to cause vasoconstriction, reducing nasal congestion.
Triprolidine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
1 capsule orally every 12 hours; each capsule contains 10 mg phenylephrine hydrochloride and 75 mg carbinoxamine maleate.
1 tablet (triprolidine 2.5 mg/pseudoephedrine 60 mg) orally every 4 to 6 hours; maximum 4 tablets per 24 hours.
None Documented
None Documented
12 hours (terminal); prolonged to 24 hours in renal impairment (CrCl <30 mL/min)
Triprolidine: 3-5 hours (terminal). Pseudoephedrine: 5-8 hours (terminal, pH-dependent; urine pH 8: ~13 hours, pH 5: ~3 hours). Clinical: normal renal function.
Renal (50% as unchanged drug), fecal (40% as metabolites), biliary (10% as glucuronide conjugates)
Triprolidine: ~80% renal (mostly metabolites, <5% unchanged). Pseudoephedrine: ~70-90% renal (43-96% unchanged, depends on urine pH; acidic urine increases elimination, alkaline decreases). Biliary/fecal: negligible for both.
Category C
Category A/B
Antihistamine/Decongestant Combination
Antihistamine